GLP1R and type 2 diabetes mellitus: Therefore, the guidelines of the European Society of Cardiology recommend GLP-1 receptor agonists as a possible first-line therapy for type 2 diabetes in patients with established atherosclerotic cardiovascular disease or in those at high or very high risk [97].